NeoGenomics: Mix Shift and Reimbursement Wins Fuel Accelerating Clinical Growth
Diagnostics leader rides NGS momentum, expands MRD indications, and raises guidance despite pharma weakness.
NEO · Earnings Call · 2026-07-28
The Clinical Engine Accelerates
NeoGenomics delivered a strong second quarter, with total revenue up 11% to $201.7M, beating guidance. Clinical revenue grew 14%, driven by a 12% increase in average unit price (AUP) and 2% volume growth. The shift toward high-value testing continues to reshape the revenue mix: NGS revenue jumped 26% and now represents one-third of clinical revenue. Mix shift is the dominant theme, as physicians adopt larger panels and higher-value liquid biopsy tests. CEO Tony Zook affirmed the durability of this trend: “we think we have a very durable position with NGS now.” — Anthony Zook, Chief Executive Officer · 2026-07-28 This builds on the narrative set in Q1, when he noted that NGS growth remains sustainable: “So we absolutely do think that it's sustainable.” — Anthony Zook, Chief Executive Officer · 2026-04-28 CFO Abhishek Jain highlighted the AUP uplift: “the mix shift towards high-value testing remained a key contributor for AUP growth of 12% year-over-year.” — Abhishek Jain, Chief Financial Officer · 2026-07-28 The company is also benefiting from continued revenue cycle management improvements, including pricing gains with a top national payer.Reimbursement Wins and Product Expansion
The company is aggressively expanding its MRD footprint. RaDaR ST, a tumor-informed MRD test, now has three additional indications pending MolDX approval, bringing the total to five if all are approved. Warren Stone noted: “If all 5 of these indications are approved, as we anticipate, we would have access to over 40% of the total addressable market for tumor-informed MRD testing.” — Warren Stone, Chief Operating Officer · 2026-07-28 These reimbursement wins are central to unlocking future growth, and the company is investing in the commercial organization in anticipation. The PanTracer family, including liquid biopsy and the new PanTracer Pro workflow, is gaining traction. The company also completed the transition of PanTracer LBx to the NovaSeq X platform, which is expected to lower per-test costs and improve throughput. NovaSeq X is a key enabler of margin expansion.Nonclinical Drag and Margin Expansion
The nonclinical business, particularly pharma services, continues to be a weak spot. Pharma revenue declined 26% in Q2, though bookings hit an all-time high. Management views the business as near a bottom but trimmed full-year expectations to a high single-digit decline. This is consistent with prior guidance: “we expect pharma to be soft in Q4 as well as throughout 2026” — Jeffrey Sherman, Chief Financial Officer · 2025-10-28 (from the October 2025 call). Despite this drag, gross margin expanded 260 basis points year-over-year to 48.1% on an adjusted basis, driven by AUP growth and the Lab of the Future initiative. Future initiatives including digital pathology, AI-assisted automation, and lab footprint optimization are expected to drive further gains. Warren Stone added: “We expect continued efficiency gains from the Lab of the Future program to support gross margin expansion goals for the remainder of the year.” — Warren Stone, Chief Operating Officer · 2026-07-28 The company continues to make progress on its margin expansion goals, with adjusted gross margin approaching 50%.Financial Position and Outlook
The company raised full-year revenue guidance to $802–806M and adjusted EBITDA to $56–58M, reflecting confidence in the clinical momentum. It also refinanced its convertible notes, raising $316M and extending maturity to 2032, strengthening the balance sheet. The stock has rallied sharply (+120% over the last 90 days) as investors recognize the turnaround, though it remains well below its 2021 peak.The company's focus on high-value oncology testing is paying off, and while the pharma headwind persists, the clinical engine is clearly accelerating. Investors are betting that reimbursement wins and margin expansion will continue to drive re-rating.With meaningful progress on our therapy selection and MRD test offerings during the second quarter, I'm excited for the remainder of the year as well as 2027 and beyond as these high-value tests represent a growing portion of our clinical business.